Dinaciclib
- Generic Name
- Dinaciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28N6O2
- CAS Number
- 779353-01-4
- Unique Ingredient Identifier
- 4V8ECV0NBQ
- Background
Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Kolkata scientists identify therapy to help cancer patients overcome resistance to current treatments
Scientists at IACS, Kolkata, identified TDP1 as a DNA repair enzyme crucial for cancer cell survival during Top1 inhibitor chemotherapy. CDK1 phosphorylates TDP1, enhancing its repair function. Targeting both CDK1 and TDP1 with inhibitors could improve treatment effectiveness and overcome drug resistance.
Breakthrough therapy by Indian scientists offers hope for patients resistant to current cancer treatments
Scientists at IACS, Kolkata, developed a novel cancer therapy targeting TDP1, a DNA repair enzyme, suggesting a combination therapy with CDK1 inhibitors to overcome drug resistance and enhance treatment effectiveness.
Breakthrough study identifies new targets for combating drug-resistant cancer
Researchers from IACS Kolkata identified CDK1 and TDP1 as key proteins in DNA repair, suggesting combination therapy with CDK1 and Top1 inhibitors to overcome cancer drug resistance.
New cancer therapy target could help patients overcome resistant to current treatments
Scientists identified TDP1 as a DNA repair enzyme crucial for cancer cell survival, suggesting CDK1 inhibitors alongside Top1 inhibitors could enhance cancer treatment, especially for resistant cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath